Johnson & Johnson announced two-year data from its Phase 3 ICONIC-TOTAL study evaluating the efficacy of ICOTYDE in treating high-impact plaque psoriasis sites. The study focused on patients with scalp and genital psoriasis, areas often difficult to treat effectively.
The results indicated high rates of site-specific complete skin clearance at Week 112. Specifically, 60% of patients with scalp psoriasis achieved complete clearance, while 89% of patients with genital psoriasis achieved the same result. These findings were presented as part of the study's ongoing evaluation of the treatment's long-term effects.
